VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
Rhea-AI Summary
VivoSim (Nasdaq: VIVS) announced an AI prediction tool, VitroSense™, trained on data from its NAMkind™ ileum and colon 3D human intestinal models to predict drug-induced diarrhea. VivoSim reports the model attained 96% predictive accuracy using a training set of dozens of compounds. The platform supports oral and IV dosing simulations and detected differential effects from antibody-drug conjugates (ADCs). NAMkind™ liver and small-intestine services are offered in the US, Europe, Korea, and China as the company scales capacity.
Positive
- 96% predictive accuracy for diarrhea risk
- Human 3D NAM models (ileum and colon) used to train AI
- Supports oral and IV administration simulations for testing
- ADC-specific detection of epithelial and payload effects
- Services available in US, Europe, Korea, China
Negative
- Model trained on a relatively limited set: dozens of compounds
- No publicly reported independent validation or peer-reviewed dataset
- Claims of transformational impact presented as company belief rather than validated outcome
News Market Reaction – VIVS
In the Apr 28 session, VIVS declined 0.67%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.1% during that session. Argus tracked a trough of -14.4% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.9x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Equity offering | Negative | +13.3% | Best-efforts public offering of up to $4.0M with warrants and two tranches. |
| Mar 24 | ADC toxicity data | Positive | -2.4% | NAMkind™ liver and intestine models validated for ADC toxicity prediction versus clinical outcomes. |
| Mar 03 | Leadership hire | Positive | -12.7% | Appointment of VP Global Sales to drive commercial expansion of liver and GI NAM services. |
| Feb 11 | Conference data | Positive | +0.0% | Planned presentation of NAMkind™ ADC validation data at Society of Toxicology meeting. |
| Jan 29 | Distribution deal | Positive | +71.8% | New distributors in Korea and China expand Asia-Pacific access to NAMkind™ services. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VIVS news often showed divergence: positive operating updates sometimes saw flat or negative moves, while a dilutive offering saw a positive reaction.
Over the last few months, VIVS has combined commercial expansion with financing moves. On Jan 29, it expanded Asia-Pacific distribution for NAMkind™ services, coinciding with a strong positive price move. Subsequent news on ADC validation and a new VP of Global Sales in March were operationally positive but met with muted or negative reactions. An early April offering of up to $4 million then drew a positive response. Today’s AI-based intestinal toxicity prediction tool builds directly on March ADC and intestine model validation themes.
Key Terms
gastrointestinal toxicity medical
intestinal epithelial integrity medical
machine‑learning analytics technical
intestinal epithelium medical
stromal layer medical
antibody-drug conjugates medical
permeability endpoints medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results
SAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the availability of an AI prediction tool leveraging its NAMkind™ intestinal models to accurately predict the potential of a given drug compound to cause diarrhea in patients. The tool integrates its proprietary NAMkind™ ileum and colon tissues with advanced machine‑learning analytics to identify drug‑induced disruptions to intestinal epithelial integrity and function. Tissue-based assay data is used to train an AI predictive model in a process VivoSim has named VitroSense™.
The model was built using a training set of dozens of compounds. Using high-quality real-world 3d NAM assay results generated from the set of training compounds, the model attained a predictive accuracy of
VitroSense™ – the use of NAMkind™-produced data to train predictive machine learning models
Central to the concept of use of NAMkind™ models in this way is its integration with its proprietary VitroSense™ toolkit that generates trained machine language models using data from its highly relevant human cell NAMkind™ tissues.
“The high biological fidelity of NAMkind™ models allows us to generate data in line with what is seen in humans” said Keith Murphy, VivoSim Executive Chairman. “By using that high-quality data to train AI models, we get much more accurate predictions. You’ve heard of “garbage in, garbage out”, but our models are the opposite: Golden raw data from NAMkind™ tissue assays is fed to the VitroSense™ model and spun into solid gold predictions for our clients’ compounds.”
NAMkind™ intestine models allow for mimicking oral or IV administration route, and are excellent for antibody drug conjugate testing.
Because of the advanced nature of the NAMkind™ intestinal model, the multilayered structure can be dosed either by mimicking oral administration or intravenous administration by exposing the relevant portion of the tissue – the epithelial lining or the stromal layer.
As recently demonstrated at Society of Toxicology, NAMkind™ intestine models were also tested with antibody-drug conjugates (ADCs) and have the ability to detect differential effects such as antibody activity on epithelium, payload impact on epithelium, and overall ADC impact on epithelium. Permeability endpoints are sensitive to the exact chemical compound, be it ADC, antibody alone, or payload.
“With
VivoSim is now working with clients to provide an effective screen for effects on the intestinal epithelium for oncology ADC candidates.
NAMKind™ liver and small intestine toxicology services are now available in US, Europe, and via local distributor engagement across Korea and China, with VivoSim continuing to scale capacity to support expanding global demand and urgent, real-world development needs.
About VivoSim Labs
VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding NAMKind™, including target turnaround time and its potential to help users de-risk their pipelines, avoid costly downstream failures, reduce rework, prioritize the right assets, move faster, save millions and reduce risk; VivoSim’s commercial presence across Asia-Pacific; the evaluation and acceptance of scientifically robust NAM-based evidence; the Company’s ability to capture growing demand in the in vitro toxicology testing market; demand for human-relevant toxicology; the market opportunity and market size of gastrointestinal in vitro models and toxicology services; and the Company’s scaling capacity to support expanding global demand and development needs. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 11, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.
